In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Criteria

Inclusion Criteria:

Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:

• Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) and measurable disease according to Lugano criteria

• MGUS/SMM according to IMWG definitions

• Age ≥18

• Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards & Guidelines) from assays obtained <2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention

• MSKCC patients

Exclusion Criteria:

• Breast-feeding

• History of renal functional disorders (chronic kidney disease with eGFR<30)

• Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)

• CNS lymphoma